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Abstract
Background: In male patients suffering from chronic pain, opioid administration induces severe hypogonadism,
leading to impaired physical and psychological conditions such as fatigue, anaemia and depression. Hormone
replacement therapy is rarely considered for these hypogonadic patients, notwithstanding the various
pharmacological solutions available.
Methods: To treat hypogonadism and to evaluate the consequent endocrine, physical and psychological changes
in male chronic pain patients treated with morphine (epidural route), we tested the administration of testosterone
via a gel formulation for one year. Hormonal (total testosterone, estradiol, free testosterone, DHT, cortisol), pain
(VAS and other pain questionnaires), andrological (Ageing Males’ Symptoms Scale - AMS) and psychological (POMS,
CES-D and SF-36) parameters were evaluated at baseline (T0) and after 3, 6 and 12 months (T3, T6, T12
respectively).
Results: The daily administration of testosterone increased total and free testosterone and DHT at T3, and the
levels remained high until T12. Pain rating indexes (QUID) progressively improved from T3 to T12 while the other
pain parameters (VAS, Area%) remained unchanged. The AMS sexual dimension and SF-36 Mental Index displayed
a significant improvement over time.
Conclusions: In conclusion, our results suggest that a constant, long-term supply of testosterone can induce a
general improvement of the male chronic pain patient’s quality of life, an important clinical aspect of pain
management.
Background
Awareness of the need to adequately treat pain, particu-
larly chronic pain, is slowly increasing among patients
and pain therapists. Opioids are among the most pre-
scribed analgesic drugs but present several side effects
such as nausea, itching, constipation and hypogonadism
[1,2]. For hypogonadism, there is clear evidence in the
literature for both humans [3-7] and experimental ani-
mals [8,9]. Symptoms and signs related to gonadal hypo-
function and consequent testosterone depletion include
peripheral effects (muscle hypotrophy, bone loss, anae-
mia, etc.) and severe and disabling central effects
(decreased attention, disappearance of libido, depressive
state, etc.). Moreover, there is much evidence for a close
relationship between testosterone and neuroprotective
processes. For instance, it was reported that older men
with low levels of free circulating testosterone appear to
be at higher risk of developing Alzheimer Disease than
men with higher levels of this hormone [10], and gona-
dal and adrenal androgen levels were found to be lower
in men and women suffering from rheumatoid arthritis
than in healthy controls [11]. In experimental animals,
testosterone administration in inflammatory painful con-
ditions, such as formalin- or adjuvant-induced pain, was
found to decrease pain-induced responses [12-14].
Opioid-induced hypogonadism in males (Opioid-
Induced Androgen Deficiency, OPIAD) is usually
ignored by pain physicians and rarely considered for
treatment [1] despite its high frequency (almost 100%)
and persistence. Daniell [1] described the beneficial
effects of testosterone replacement in opioid-treated
patients for six months.
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course/interactions between opioids and testosterone
replacement therapy in a clinical sample of male chronic
pain patients diagnosed with OPIAD and receiving mor-
phine via the epidural route. This kind of patient was
chosen to reduce variables due to the high numbers of
opiates available, their dosage and combinations. More-
over, all these patients had been suffering from chronic
pain for many years and their pain condition was con-
sidered severe and stable. To obtain a broad picture of
the effects induced by this treatment, we considered dif-
ferent aspects using a multidisciplinary approach. A
team of experts, namely an andrologist, a psychologist,
the project co-ordinator and a local pain therapist, met
with each patient monthly for one year to check the
clinical and laboratory outcomes. Testosterone was
replaced via a gel formulation able to restore and main-
tain testosterone levels [15] by virtue of the fact that its
application on the skin prevents first liver clearance and
allows steroids to be directly absorbed and stored in the
stratum corneum. From this reservoir, testosterone or
its metabolites (17-beta estradiol and DHT) are slowly
released into the circulation over several hours. Testos-
terone and its related hormones (estradiol, DHT) were
measured in the blood, together with cortisol as an
index of adrenal activity. Pain intensity and its features
were studied with the VAS, the Italian version of the
McGill Questionnaire (QUID) and the Margolis method
to determine the percentage of the body in pain. The
andrological condition was studied with the dedicated
questionnaire Ageing Males’ Symptoms Scale (AMS),
and different aspects of the psychological characteristics
were evaluated through questionnaires able to study
anxiety, depression and quality of life (POMS, CES-D
and SF-36). The study was carried out for 12 months.
The results suggest beneficial effects on the patients’
quality of life.
Methods
Subjects
Male chronic pain patients referred to two Italian pain
centres (Forlì, Cagliari) were asked to take part in this
study. To obtain the most homogeneous group of
patients possible, only male subjects suffering from non-
oncological chronic pain and undergoing epidural mor-
phine were considered; morphine treatment had to have
been carried out for at least six months; hypogonadism
was diagnosed for testosterone values less than 2-3 ng/
mL in at least two determinations in the previous 3-4
months. Other inclusion criteria were the presence of
clear symptoms indicative of hypogonadism (fatigue,
depressed mood, decreased libido) and negative urologi-
cal problems. Experimental procedures were carried out
in agreement with the Code of Ethics of the World
Medical Association (Helsinki Declaration) and were
approved by the Local Ethics Committee.
Once included in the study, each subject met with the
experimental team once a month for one year during
the morphine pump refilling session and underwent
clinical, psychological and hormonal evaluations. In par-
ticular, the following procedures were performed during
the monthly meeting:
- Blood collection,
- Complete clinical evaluation by the pain therapist,
including the administration of specific pain ques-
tionnaires for pain assessment (VAS, QUID, Area%),
- Psychological evaluation, including the administra-
tion of specific questionnaires for anxiety, depression
and quality of life (POMS, CES-D, SF-36),
- Andrological evaluation, including manual explora-
tion of the prostate and transrectal prostate echogra-
phy when necessary. The patient was asked to
complete a specific andrological questionnaire
(AMS). The subject was also examined for any
adverse effects that might be related to the gel,
including local skin irritation. At each visit, the sub-
ject was given a one-month supply of testosterone
gel, a hydroalcoholic compound containing 50 mg
testosterone in 5 g gel in each sachet. So as not to
introduce other variables, the dose of testosterone gel
was maintained constant independently of the blood
testosterone levels shown by the patient. The patient
was asked to apply the gel on the skin of the upper
arm/shoulder or abdomen each morning at the same
time, alternating the site of application each day and
not taking a shower until 5 hours after application.
He received verbal instructions to record in a diary
any change that may have occurred in his daily activ-
ities and physical and mental performances.
All procedures took about 2 hours per patient per
month.
Questionnaires
All questionnaires were self-administered, but supported
by the presence of the expert clinician.
Pain assessment
A Visual Analogue Scale, VAS (0-100), was used [16] to
estimate the current intensity of pain and the peak
intensity during the previous week. VAS is a 10 cm hor-
izontal line, anchored at the extremes by “no pain “ and
“worst pain possible”.
The quality and intensity of the current pain experience
was evaluated by the Italian Pain Questionnaire, QUID
[17]. The QUID is a reconstructed Italian version of the
McGill Pain Questionnaire (MPQ). It is a semantic interval
scale consisting of 42 descriptors divided into four main
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Pain Rating Index rank value (PRIr) for each dimension
and for the whole experience (Pain Rating Index rank-
Total [PRIr-T], given by the sum of all the rank values)
indicate the quality and intensity of pain.
The percentage of body surface area in pain (Area%)
was measured according the Margolis method [18]. It
consists of a human front-back body map in which the
patient marks the area in pain. Thus, the drawing gives
the pain distribution and the percentage of body surface
area affected by pain.
Andrological and urological evaluation
The impact of treatment on the androgens-related qual-
ity of life was measured by the Ageing Males’ Symptoms
scale (AMS) questionnaire [19]. The AMS is composed
of three subscales, measuring respectively: psychological,
somatic and sexual symptoms. Items (n = 17) are scored
on a 1 (absent) to 5 (very severe) Likert scale. The sum-
score for each subscale is obtained by adding up the rat-
ings of the items. The total score is the sum of the three
subscale ratings. The higher the value, the worse the
condition of the subject. The severity categories are:
mild (27-36), moderate (37-49), severe (≥50).
Psychological evaluation
To study psychological characteristics of the patients
and their time course, the following questionnaires were
administered:
Profile of Mood State (POMS). The POMS measures
the current psychological state of the participant [20]
and consists of 58 feelings rated on a 5-point scale. It
comprises six subscales: Tension-Anxiety (T-A), Depres-
sion-Dejection (D-D), Anger-Hostility (A-H), Vigor-
Activity (V-A), Fatigue-Inertia (F-I) and Confusion-
Bewilderment (C-B). In each subscale, values higher (T-
A, D-D, A-H, F-I and C-B) or lower (V-A) than 55 were
considered significantly altered with respect to the nor-
mal population [21].
Centre for Epidemiological Studies Depression Scale
(CES-D). The Italian version of CES-D [22] was used to
determine the level of depression symptoms for research
purposes [23]. The CES-D is a 20-item self-reported
measure of symptoms, scored on a scale from 0 to 3 fre-
quency ratings ("less than 1 day” to “most or all (5-7)
days”) for symptoms within the past week. Previous stu-
dies have verified that a score of 16 or above on the
CES-D indicates clinically significant depressive symp-
toms [23].
Italian version of the SF-36 [24] questionnaire. SF-36
is a 36-item questionnaire measuring the patient’s level
of performance in eight health domains: Physical Func-
tioning, Role Physical (role limitations caused by physi-
cal problems), Social Functioning, Bodily Pain, Mental
Health, Role Emotional (role limitations caused by emo-
tional problems), Vitality and General Perception of
Health. Individual items are scored on a 0-100 standar-
dized Likert scale. For each domain, including Bodily
Pain, a higher score indicates a better quality of life.
Two indices (Physical and Mental) based on pertinent
subscale clustering summarize the respective function-
ing. Due to the critical conditions shown by most of the
patients at the beginning of the observations, some of
the SF-36 data related to physical evaluation were lost.
Thus only the Mental Index (MI) was taken into
consideration.
Hormones
Blood was collected between 8.00 and 10.00 am in one
EDTA-added tube (5 ml to obtain plasma) and one
empty tube (10 ml to obtain serum). In addition to gen-
eral laboratory exams performed locally (including albu-
min levels), serum and plasma samples were taken to
the Stress and Pain Neurophysiology Laboratory of the
University of Siena, where the following hormones were
determined at baseline (T0), 3 (T3), 6 (T6) and 12 (T
12) months: total testosterone (TT), free testosterone
(fT), dihydrotestosterone (DHT), estradiol (E2), sex hor-
mone-binding globulin (SHBG), cortisol (C). Prostate-
specific antigen (PSA) was determined each month.
These values were used to calculate bioavailable testos-
terone (BioT) through the website http://www.issam.ch/
freetesto.htm, according to Vermeulen’s formula [25].
Total testosterone (TT) was measured by RIA using a
kit from RADIM (Pomezia, Italy). The cross reactivity of
the antiserum coated in the tubes was 5.6% for DHT,
1.6% for androstenedione and lower than 0.1% for
androstenediol, SHBG, estrone, DHEAS, estradiol. The
lower limit of quantitation of TT measured by this assay
was 0.017 ng/mL. The intra- and inter-assay coefficients
were 1.5% and 7.8%, respectively, at the normal adult
male range: 3.5-8.5 ng/mL in our laboratory.
Free testosterone (fT) was measured by RIA using a
kit from Diagnostic Systems Laboratories (Webster,
Texas, USA). The cross reactivity of the antiserum
coated in the tubes was 0.35% for 19-nor testosterone,
0.21% for 17 alpha-methyltestosterone, 0.13% for 11-
oxo-testosterone and non-detectable reactivity for DHT,
DHEA, DHEA-S, progesterone, estradiol, corticosterone
and other androgens. The lower limit of quantitation of
fT measured by this assay was 0.18 pg/mL. The intra-
and inter-assay coefficients were 4.5% and 7.9%, respec-
tively, at the normal adult male range: 14.7-32.7 pg/mL
in our laboratory.
Sex hormone-binding globulin (SHBG) was mea-
sured by IRMA using a kit from Diagnostic Systems
Laboratories (DSL, Webster, Texas, USA). Concerning
the specificity, no human serum protein is known to
cross react with the antibodies employed in the DSL
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SHBG measured by this assay was 3 nmol/L. The intra-
and inter-assay coefficients were 2.7% and 10.2%,
respectively, at the normal adult male range: 28-94
nmol/L in our laboratory.
Dihydrotestosterone (DHT) was measured by RIA
using a kit from Diagnostic Systems Laboratories (Web-
ster, Texas, USA). The cross reactivity of the antiserum
coated in the tubes was 3.3% for androstandiol glucuro-
nide, 0.6% for testosterone, 0.03% for androstandiol and
no reactivity for androstenedione, estradiol, androster-
one glucuronide, dehydroepiandrosterone, cortisol,
deoxycortisol, 17 alpha-OH progesterone, progesterone.
The lower limit of quantitation of DHT measured by
this assay was 4 pg/mL. The intra- and inter-assay coef-
ficients were 5.5% and 9.5%, respectively, at the normal
adult male range: 250-750 pg/mL in our laboratory.
Estradiol (E2) was measured by RIA using an ultra-
sensitive kit from Diagnostic Systems Laboratories
(Webster, Texas, USA). The cross reactivity of the anti-
serum coated in the tubes was 2.4% for estrone, 0.21%
for 17 alpha-estradiol and 16 keto-estradiol, 0.64% for
estriol. The lower limit of quantitation of E2 measured
by this assay was 2.2 pg/mL. The intra- and inter-assay
coefficients were 6.5% and 9.3%, respectively, at the nor-
mal adult male range: 10.0-25.1 pg/mL in our
laboratory.
Cortisol (C) was measured by RIA using a kit from
RADIM (Pomezia, Italy). The present method has not
shown cross reaction with the following steroids: estra-
diol, testosterone, prednisone, cortisone, corticosterone,
deoxycorticosterone and 11-deoxycortisol. The lower
limit of quantitation of serum C measured by this assay
was 0.9 microg/L. The intra- and inter-assay coefficients
were 4.9% and 7.9%, respectively, at the normal adult
male range: 50-250 microg/L in our laboratory.
Prostate-specific antigen (PSA) was measured by
IRMA using a kit from Diagnostic Systems Laboratories
(DSL, Webster, Texas, USA). Ferritin, hCG, prolactin,
atropine, flutamide, diethylstilbesterol, acetylsalicylic
acid, caffeine, ibuprofen, indomethacin do not interfere
with the measurement of PSA in the DSL-9700
ACTIVE
® PSA coated-Tube IRMA assay. The lower
limit of quantitation of serum PSA measured by this
assay was 0.013 ng/mL. The intra- and inter-assay coef-
ficients were 4.6% and 9.8%, respectively, at the normal
adult male range: 0.42-2.20 ng/mL in our laboratory.
Statistical analysis
Data are expressed as mean ± SEM. Changes of the data
across time were analysed by Friedman analysis of var-
iance (ANOVA) and Kendall concordance. To better
define any possible drug effect, we compared the values
at each time of observation (T3, T6 and T12) with the
basal level (T0) using the non-parametric Wilcoxon test.
All analyses were performed with Statistica software. A
level of P ≤ 0.05 was considered statistically significant.
Results
In the six-month period devoted to patient selection, 25
outpatients referred to the pain clinics involved in the
study and meeting the inclusion criteria were asked to
participate; 17 of them met the enrolment criteria and
signed a written informed consent form. The study
design was prospective, pre-post analysis. All patients
were affected by intractable non-cancer chronic pain
treated for many years with different pharmacological
regimens until the present when they received morphine
(epidural route). In some instances, as in tetraplegic
patients, morphine was associated with an adjuvant
(baclofen, see Table 1). Neuropathic pain was the most
common pain type, while pain from chronic pancreatitis
was present in three subjects.
Of the 17 men included in the study (Table 1), three
abandoned it within the first month and two after the
third month for reasons independent of the study. In
two subjects the immediate appearance of headache and
in one subject the occurrence of urinary block obliged
them to leave the study. The remaining 9 subjects (age
59.0 ± 4.4, range: 38-74) completed the 12 months of
observation (Table 1). In these patients, it was not
necessary to include any other treatment (i.e. phy-
siotherapy, counselling) during the one-year study.
Clinical observations
In all patients, treatment appeared to be immediately
effective, as verbally confirmed during the interview by
the patients and their relatives. Indeed, starting from the
first month, patients reported general changes such as
faster beard growth and increased appetite. Manual
prostate exploration never revealed clinically relevant
features and the PSA levels always remained within the
physiological range (<3 ng/mL, mean 0.8 ng/mL).
Morphine dose
The morphine dose was changed according to patient
r e q u i r e m e n t s( F i g u r e1 ) .T h ed o s er e m a i n e ds t a b l ei n
three patients, was decreased in two subjects and was
increased in four. The last group included patients in
which the improved general condition allowed a mor-
phine increase in the attempt to complete the pain
relief. This was made possible by the lesser number of
side effects reported.
Pain assessment
VAS Both VAS values (current and last week peak) were
high and not modified by treatment; ANOVA did not
show any significant variations (c
2 = 3.98, p = 0.26 and
c
2 = 3.86, p = 0.27, respectively) (Table 2).
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remained stable across time (ANOVA: c
2 =1 . 7 4 ,p=
0.63) (Table 2).
QUID In all patients, the QUID values at T0 were quite
high in total and partial ratings. Over time, there was a sig-
nificant decrease in the PRIr-Total (c
2 = 13.87, p < 0.003)
and in the sensory (c
2 = 8.29, p < 0.04), affective (c
2 =
8.06, p < 0.04) and evaluative PRIr (c
2 = 11.08, p < 0.01).
The PRIr-sensory and PRIr-evaluative were already lower
at T3 (p < 0.018 for both), the miscellaneous at T6 (p <
0.046) and the PRIr-affective at T12 (p < 0.046) (Table 2).
Andrological evaluation
AMS scale The mean baseline score of AMS Total was
44.1 ± 4.1. This value indicates “moderate” andrological
impairment. Detailed analysis of the subscale ratings
revealed that there was a significant decrease, i.e.
improvement, of the ‘sexual’ dimension (ANOVA: c
2 =
8.77, p < 0.03) (Table 3).
Psychological outcomes
POMS, CES-D and SF-36 All the basal values obtained
in these questionnaires were outside the ‘normal’ ranges.
In particular, POMS was higher than 55 in all subscales
except Vigor-Activity (lower than normal), while CES-D
was always higher than 16 and SF-36 lower than 50.
N o n eo ft h eP O M Ss u b s c a l es c o r e so rC E S - Dr a t i n g s
showed significant changes, while the SF-36 Mental
Index displayed a significant improvement over time
(ANOVA: c
2 = 11.35, p = 0.009); in particular, the
score increased progressively to become significantly
higher at T12 than at T0 (p < 0.04) (Table 4).
Hormonal parameters
Testosterone administration via gel is known to increase
total testosterone serum levels immediately, reaching a
steady state in 1-2 weeks [26]. Thus, the first result is
Table 1 Personal and clinical data of the selected male patients
Patients Age Pathology Therapy Total testosterone basal
(ng/ml)
1 47 Hypertonic tetraplegia Spinal
lesion
i.t. morphine +
baclofen
1.18
2 60 Chronic pancreatitis i.t. morphine 0.8
3 40 Lumbosacral radiculopathy i.t. morphine +
baclofen
2.94
4 67 Lumbosacral neuralgia i.t. morphine +
marcaine
0.3
5 58 Neurinoma i.t. morphine 0.94
6 44 Spinal surgery i.t. morphine 1.05
7 71 Lumbosacral radiculopathy i.t. morphine 0.51
8 68 Lumbosacral radiculopathy i.t. morphine 1.4
9 75 Coccygodynia i.t. morphine 0.97
10 43 Spinal lesion i.t. morphine +
durogesic
0.49 Interrupted after three months for personal
reasons
11 64 Chronic pancreatitis i.t. morphine 1.19 Interrupted after three months for personal
reasons
12 55 Chronic pancreatitis i.t. morphine 0.75 Interrupted for personal problems
13 74 Spinal lesion i.t. morphine 1.16 Interrupted for personal problems
14 58 Myelopathy i.t. morphine +
baclofen
1.42 Interrupted for personal problems
15 72 Spinal lesion i.t. morphine +
baclofen
0.73 Urinary block
16 67 Myelopathy i.t. morphine 3 2.1 Headache
17 79 Lumbosacral radiculopathy i.t. morphine 1.94 Headache
Total testosterone values are reported to prove the hypogonadic condition. Reference range of total testosterone values: 3.5-8.5 ng/ml.
Figure 1 Morphine dose assessment. Time course of the
morphine dose at basal time (T0) and after 3, 6 and 12 months of
testosterone replacement therapy (T3, T6 and T12, respectively) in
patients participating in the entire study. The lines represent the
time course of the individual patients numbered as in Table 1.
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in body features (beard and hair increase) and in some
habits closely dependent on androgens (increased food
intake), the first significant increase in blood levels only
occurred after 2 months of treatment as shown in the
insert in Figure 1 where is depicted the time monthly
time course recorded in the first 4 patients monitored
to evaluate the efficacy of treatment.
Total testosterone (TT), free testosterone (fT), bioavailable
testosterone (BioT) and SHBG
Total (TT), free (fT) and bioavailable testosterone
(BioT) showed very low levels at T0 (TT 1.16 ± 0.28
ng/mL; fT 4.33 ± 0.89 pg/mL, BioT 0.34 ± 0.1 ng/dL)
with respect to the normal range, while SHBG was close
to the upper limit of the normal range (77.77 ± 12.12
nmol/L) (Figure 2). Daily administration of testosterone
significantly increased the TT serum levels at T3,
remaining at approximately t h es a m el e v e lu n t i lT 1 2 ;
there were similar results for fT, which became signifi-
cant at T12 (p < 0.028). BioT was significantly increased
at T3 (p < 0.028) and remained significantly higher at
T6 (p < 0.05) and at T12 (p < 0.018).
To evaluate the ratio between the unbound fraction
(fT) and TT, we calculated a percentage (%fT). The %fT
tended to decrease at T3, but did not reach significance.
SHBG did not change significantly (Figure 3, Table 5).
Serum levels and ratios of the testosterone metabolites
The two metabolites of testosterone, DHT and E2,
changed differently. DHT increased progressively, reach-
ing significance at T12 (p < 0.02), whereas E2 did not
vary. The ratio DHT/TT did not change while the ratio
E2/TT was decreased significantly already at T3 and
remained stable till T12 (p < 0.015, p < 0.021 and p <
0.011 at T3, T6 and T12, respectively).
Cortisol showed a slow, non-significant reduction dur-
ing the one-year therapy (Table 5).
Discussion
Evidence from this study suggests that one year of tes-
tosterone replacement therapy in male patients suffering
from a severe form of chronic pain and diagnosed with
morphine-induced hypogonadism (OPIAD) is able to
positively change hormonal and behavioural ‘indicators’
chosen to measure different aspects of their condition.
Although pain research is continuously coming up
with new products to treat chronic pain, opioids remain
the reference therapy. Unfortunately this approach
involves several side effects, which increasing morbidity
would induce the discontinuation of therapy [27]. With
continued opioid use, many side effects diminish or
resolve; conversely, others such as immune alteration
and hypogonadism persist and are even more apparent
after long-term therapy [3,4,28]. The subjects considered
Table 3 Andrological assessment
Parameter Months
T0 T3 T6 T12
AMS Psychological 11.00 ± 2.17 13.50 ± 2.67 9.28 ± 1.59 12.14 ± 1.95
AMS Somatic 15.57 ± 2.29 22.85 ± 2.25 20.85 ± 1.76 21.28 ± 1.91
AMS Sexual 14.14 ± 2.15 13.78 ± 1.85 9.71 ± 1.08* 10.42 ± 1.25*
AMS Total 44.14 ± 4.10 50.14 ± 5.63 39.85 ± 3.03 43.42 ± 4.00
AMS scale scores recorded before (T0) and after 3 (T3), 6 (T6) and 12 (T12) months of testosterone replacement therapy. Values are mean ± SEM (n = 9).
Wilcoxon test: *p < 0.03 vs T0.
Table 2 Pain assessment
Parameter Months
T0 T3 T6 T12
VAS (0-100) 67.14 ± 10.9 75.57 ± 6.44 66.42 ± 9.36 64.28 ± 9.15
VAS last week (0-100) 62.00 ± 11.15 82.85 ± 5.10 77.14 ± 6.80 72.14 ± 5.96
Area % 30.78 ± 10.03 29.04 ± 8.17 30.28 ± 7.77 31.00 ± 7.12
QUID Sensory 20.85 ± 1.86 14.57 ± 2.33* 12.85 ± 2.47# 16.00 ± 2.96
QUID Affective 11.14 ± 1.69 8.71 ± 1.71 7.57 ± 2.63 7.14 ± 2.07#
QUID Evaluative 17.28 ± 1.78 10.71 ± 2.75* 10.85 ± 2.82§ 10.28 ± 2.92#
QUID Miscellaneous 11.71 ± 0.64 7.42 ± 1.81 6.14 ± 1.79§ 7.00 ± 2.03
QUID Total 61.00 ± 5.06 41.42 ± 7.62* 37.42 ± 9.05* 40.42 ± 8.83*
VAS, Area% and QUID, values recorded before (T0) and after 3 (T3), 6 (T6) and 12 (T12) months of testosterone replacement therapy. Values are mean ± SEM
(n = 9). Wilcoxon test: *p < 0.01 vs T0; #p < 0.02 vs T0; § p < 0.04 vs T0.
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clearly suffering from hypogonadism, as revealed by the
low plasma testosterone levels and/or clinical symptoms
indicative of this condition.
Testosterone replacement therapy is a common
approach in ageing males with partial androgen deficit
or in young hypogonadic men due to traumatic or surgi-
cal causes; in these subjects, testosterone administration
via gel is known to increase total testosterone serum
levels immediately, reaching a steady state in 1-2 weeks
[26]. Thus, it must be underlined that, although all our
patients exhibited visible changes in body features
(beard and hair increase) and in some habits closely
dependent on androgens (increased food intake), the
first significant increase in blood levels only occurred
after 2 months of treatment. Further research is needed
to better study the possible interaction among pain,
opioid and androgen metabolism.
Several hypotheses have been advanced to explain
OPIAD [29]. One suggests that the hypogonadism is
due to opioid-induced inhibition of gonadotropin release
[30]; however, another hypothesis suggests that the inhi-
bitory action is also exerted in the gonads. Indeed,
opioid receptors have been described in the pituitary as
well as in the gonads, and opioids have been found to
up-regulate their own receptors. Another mechanism
involves testosterone metabolism. It is known that mor-
phine increases 5-alpha reductase activity [9] and we
have shown an excitatory effect on aromatase activity in
vitro [31] and of both enzymes in ex-vivo tissues [32];
these enzymes, present in the liver but also widespread
in body tissues, are involved in the transformation of
testosterone to its metabolites dihydrotestosterone
(DHT) and estradiol.
Finally, we cannot exclude either a direct effect of pain
on the HPG axis, since observations have indicated a
depressant effect of experimental pain on testosterone
blood and brain levels in rats through the stress system,
or the quite common use of other drugs able, like
opioids, to inhibit the HPA axis [32,33].
Andrology
While the psychological and somatic aspects of the
painful condition are usually taken into consideration by
physicians, the sexual aspect of the patient’s life is gen-
erally disregarded. In the present study, as in a previous
one by Daniell’s group [1], the andrological question-
naires administered at the beginning of the observations
confirmed the presence of altered conditions in all
patients, probably related not only to pain but also to
the altered hormone levels. Indeed also in the present
study, the AMS revealed ‘moderate’ andrological distur-
bances, indicating the presence of clinically relevant
alterations. As expected, testosterone replacement pro-
gressively improved the sexual aspect, as confirmed by
the AMS’s sexual dimension.
Table 4 Other questionnaires
Parameter Months
T0 T3 T6 T12
POMS Tension-Anxiety 60.14 ± 6.14 65.71 ± 5.42 53.14 ± 4.86 58.71 ± 4.32
POMS Depression-Dejection 63.42 ± 7.16 70.28 ± 6.75 58.14 ± 6.69 65.00 ± 6.88
POMS Anger-Hostility 66.00 ± 7.45 68.14 ± 7.35 60.14 ± 4.36 61.85 ± 4.83
POMS Vigor-Activity 44.14 ± 3.90 37.28 ± 3.34 44.00 ± 3.50 42.28 ± 5.42
POMS Fatigue-Inertia 66.85 ± 7.25 72.00 ± 6.20 64.14 ± 6.42 64.56 ± 6.11
POMS Confusion-Bewilderment 60.85 ± 7.64 68.28 ± 7.66 58.28 ± 5.81 61.14 ± 7.22
SF-36 Mental Index 39.42 ± 5.98 35.00 ± 3.65 45.57 ± 4.33 48.42 ± 3.73*
CES-D 21.14 ± 6.55 27.85 ± 5.09 25.14 ± 4.71 22.71 ± 5.25
Scores of POMS, SF-36 and CESD questionnaires administered before (T0) and after 3 (T3), 6 (T6) and 12 (T12) months of testosterone replacement therapy.
Values are mean ± SEM (n = 9). Wilcoxon test: *p < 0.04 vs T0.
Figure 2 Serum total testosterone. Serum total testosterone (TT)
values at basal time (T0) and after 3 (T3), 6 (T6) and 12 (T12)
months of testosterone replacement therapy. The insert reports the
TT levels at basal time (T0) and 1, 2 and 3 months from the
beginning of testosterone replacement therapy (T1, T2 and T3,
respectively) of the first four patients used to evaluate the time
course of tissue androgen permeation. Data are mean ± SEM. *p <
0.05 vs T0.
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We provide preliminary data suggesting that the pain
experience, as assessed by QUID (a validated Italian pain
questionnaire), is affected by testosterone replacement.
In fact, QUID dimensions improved by the third month,
reaching the best values at the sixth month. This was a
very substantial result present in all subjects. QUID was
more sensitive than the other pain measurement tools
administered (VAS, %Area), probably because the ques-
tionnaire is composed of a series of descriptors requiring
patients to carefully analyse and define the ongoing pain
experience. Furthermore, since this instrument studies
Figure 3 Hormonal parameters evaluation. Serum dihydrotestosterone (DHT, A), estradiol (E2, B), DHT/T ratio (C), E/T ratio (D), bioavailable
testosterone (BioT, E) and free testosterone (fT, F) values at basal level (T0) and after 3, 6 and 12 months of testosterone replacement (T3, T6
and T12, respectively). Data are mean ± SEM. *p < 0.05 vs T0.
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sory, evaluative, affective), we were able to verify that all
these components benefited from the testosterone ther-
apy, albeit following different time courses.
T h em o r p h i n ed o s em a t c h e dt h ec h a n g ei np a i n
shown by QUID. Although three subjects asked for
escalating doses to complete the pain relief (also in vir-
tue of the low side effects they experienced), the others
maintained or reduced the morphine amount, thus
implicitly expressing pain amelioration. The results of
the SF-36 Mental Index agreed with these findings, as
they indicated an improvement in the respective
domains, i.e. daily activities, emotional competence and
social relations. Of course, the improvement in these
aspects may have positively influenced the pain percep-
tion and vice versa, since a virtuous circle was
established.
The extension and distribution of the body surface area
in pain remained unchanged, as did the VAS scores.
From the beginning of the epidural morphine administra-
tion, all the patients complained that the last week before
the refill was the worst of the month, even though the
dose of morphine was repeatedly verified to be constant
in the last days of the cycle. Our interpretation of the
high VAS scores involves two mechanisms, the one invol-
ving patient attitudes and the other the instrument itself.
Very long-lasting and unresponsive pain is not easily
consciously modified since a feeling of helplessness is
unavoidable in these subjects, impeding their realization
that any change has occurred, especially when it is posi-
tive. VAS does not contrast this attitude. Due to its over-
simplified nature, it does not require the patient to
analyse and weigh his pain, and it facilitates recollection
bias. In the end, the patient under-evaluates the measure-
ment and over-emphasizes the pain he is rating. The
findings on QUID, which requires the patient to focus on
his experience, match perfectly with this explanation,
making this instrument more reliable in the setting
described herein. Interestingly these results are very simi-
lar to those reported by Daniell and colleagues (2006) [1],
in which the general improvement of living conditions
provided by patch testosterone replacement were not fol-
lowed by a clear decrease in pain measures.
The affective state of chronic pain is characterized by
deep depression and high anxiety; sometimes such an
affective condition depends not only on the pain severity
but also on the underlying disease, especially when it is
highly vexing and disabling. Our patients were affected
by intense long-lasting pain and a serious illness. Thus,
they were anxious and depressed, as shown by the
POMS and CES-D scores. These ratings did not vary
throughout the observational period, indicating that tes-
tosterone therapy did not influence the patients’ affec-
tive state. It is likely that the sense of uncontrollability
of their condition was so deeply rooted in their mind
that it was not easily attenuated. On the other hand, the
improvement of pain was incomplete and too recent
with respect to its history for the attitudes toward it to
be changed. Furthermore, the patients knew that their
disease was incurable. Interestingly the persistent high
levels of anxiety and depression indicate that the
decrease of pain shown by QUID cannot be attributed
to the psychological component of the pain experience,
as may occur in purposely treated chronic pain patients.
Conclusions
The present results, although carried out in a small
number of subjects and with a constant treatment dose,
underline the possibility of successful testosterone repla-
cement therapy in chronic pain patients treated with
morphine. Hypogonadism is a usual consequence of
opioid treatment, but it is rarely taken into considera-
tion. Our results strongly suggest that this therapy can
positively modulate the dimensions of pain. This effect
Table 5 Hormonal parameters
Parameter (normal range) Months
T0 T3 T6 T12
TT (3.5-8.5 ng/mL) 1.16 ± 0.28 2.72 ± 0.69** 2.18 ± 0.51* 2.99 ± 0.47**
fT (14.7-32.7 pg/mL) 4.33 ± 0.89 7.55 ± 2.34 6.76 ± 1.79 10.57 ± 1.88*
BioT (ng/dL) 0.34 ± 0.1 0.94 ± 0.28* 0.96 ± 0.45* 1.17 ± 0.34*
SHBG (28-94 nmol/L) 77.77 ± 12.12 89.41 ± 20.0 79.76 ± 15.7 54.15 ± 7.22
%f T 0.41 ± 0.04 0.31 ± 0.06 0.31 ± 0.02 0.36 ± 0.04
DHT (250-750 pg/mL) 248.65 ± 32.10 903.7 ± 321.9 582.45 ± 125.9 796.04 ± 137.22*
E2 (10-25 pg/mL) 10.84 ± 1.23 11.65 ± 1.09 12.03 ± 1.71 12.43 ± 2.13
DHT/TT 0.29 ± 0.03 0.28 ± 0.04 0.27 ± 0.02 0.29 ± 0.038
E2/TT 0.01 ± 0.003 0.006 ± 0.001** 0.007 ± 0.0007* 0.005 ± 0.001**
C (50-250 ng/mL) 164.04 ± 30.72 150.2 ± 22.1 131.58 ± 19.74 129.97 ± 15.57
TT: total testosterone, fT: free testosterone; BioT: bioavailable testosterone; SHBG: steroid hormone binding globuline; %fT: percentage of free testosterone; DHT:
dehydrotestosterone; E2: estradiol; C: cortisol. Hormone levels determined before (T0) and after 3 (T3), 6 (T6) and 12 (T12) months of testosterone replacement
therapy. Values are mean ± SEM (n = 9). Wilcoxon test: *p < 0.05 vs T0; **p < 0.01 vs T0.
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Page 9 of 10allows us to propose the use of testosterone in clinics as
an adjuvant, in combination with opioid therapy.
Acknowledgements
We thank Dr. Cinci, Dr. Fiorenzani and all the personnel of the different pain
centres for their great help during the experiment. The study was funded by
University of Siena to AAM (q.s.) and an unrestricted contribution from
Bayer.
Author details
1Department of Physiology, Section of Neuroscience and Applied Physiology,
University of Siena, Siena, Italy.
2San Carlo Clinic, Paderno Dugnano, Milano,
Italy.
3Pain Medicine Unit, Villa Serena Hospital and Advanced Algology
Research, Forlì, Italy.
4Pain Medicine Unit, ASL Cagliari, Cagliari, Italy.
5Department of Urology “Misericordia” Hospital, Grosseto, Italy.
Authors’ contributions
AMA, IC, VB and GP conceived and supervised the project and edited the
manuscript.
IC, GdP, MC, AS, GS, SM, VP, LR, GP participated in the experimental process
and data analysis. All authors contributed to data interpretation. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 3 November 2010 Accepted: 18 February 2011
Published: 18 February 2011
References
1. Daniell HW, Lentz R, Mazer NA: Opel-label pilot study of testosterone
patch therapy in men with opioid-induced androgen deficiency. J Pain
2006, 7:200-210.
2. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E: Opioids for chronic non
cancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006,
174:1589-1594.
3. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H,
Verlooy J, Van Havenbergh T, Smet M, Van Acker K: Endocrine
consequences of long-term intrathecal administration of opioids. J Clin
Endocrinol Metab 2000, 85:2215-2222.
4. Aloisi AM, Pari G, Ceccarelli I, Vecchi I, Ietta F, Lodi L, Paulesu L: Gender-
related effects of chronic non-malignant pain and opioid therapy on
plasma levels of macrophage migration inhibitory factor (MIF). Pain 2005,
115:142-151.
5. Daniell HW: Hypogonadism in men consuming sustained-action oral
opioids. J Pain 2002, 3:377-384.
6. Daniell HW: Opioid endocrinopathy in women consuming prescribed
sustained-action opioids for control of nonmalignant pain. J Pain 2008,
9:28-36.
7. Fraser LA, morrison D, Morley-Forster P, Paul TL, Tokmakejian S, Larry
Nicholson R, Bureau Y, Friedman TC, Van Uum SH: Oral opioids for chronic
non-cancer pain: higher prevalence of hypogonadism in men than in
women. Exp Clin Endocrinol Diabetes 2009, 117:38-43.
8. Ceccarelli I, De Padova AM, Fiorenzani P, Massafra C, Aloisi AM: Single
opioid administration modifies gonadal steroids in both the CNS and
plasma of male rats. Neuroscience 2006, 140:929-937.
9. Amini H, Ahmadiani A: In vivo evidence for an increase in 5 alpha-
reductase activity in the rat central nervous system following morphine
exposure. Int J Dev Neurosci 2005, 23:621-626.
10. Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM,
Resnick SM: Free testosterone and risk for Alzheimer disease in older
men. Neurology 2004, 62:188-193.
11. Straub RH, Cutolo M: Involvement of the hypothalamic-pituitary-adrenal/
gonadal axis and the peripheral nervous system in rheumatoid arthritis:
viewpoint based on a systemic pathogenetic role. Arthritis Rheum 2001,
44:493-507.
12. Harbuz MS, Perveen-Gill Z, Lightman SL, Jessop DS: A protective role for
testosterone in adjuvant-induced arthritis. Br J Rheumatol 1995,
34:1117-1122.
13. Gaumond I, Arsenault P, Marchand S: The role of sex hormones on
formalin-induced nociceptive responses. Brain Res 2002, 958:139-145.
14. Aloisi AM, Ceccarelli I, Fiorenzani P, De Padova AM, Massafra C:
Testosterone affects pain-related responses differently in male and
female rats. Neurosci Lett 2004, 361:262-264.
15. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ,
Weber T, Berman N, Hull L, Swerdloff RS: Long-term testosterone gel
(AndroGel) treatment maintains beneficial effects on sexual function
and mood, lean and fat mass, and bone mineral density in hypogonadal
men. J Clin Endocrinol Metab 2004, 89:2085-2098.
16. Huskisson EC, Jones J, Scott PJ: Application of Visual-Analogue Scales to
the measurement of functional capacity. Rheumatol Rehabil 1976,
15:185-187.
17. De Benedittis G, Massei R, Nobili R, Pieri A: The Italian Pain Questionnaire.
Pain 1988, 33:53-62.
18. Margolis RB, Tait RC, Krause SJ: A rating system for use with patient pain
drawings. Pain 1986, 24:57-65.
19. Saccò M: Validazione culturale e linguistica di un questionario per
definire il deficit androgenico nell’invecchiamento maschile. G Gerontol
2004, 52:74.
20. McNair DM: EdITS manual: profile of mood states Educational and Industrial
Testing Service. San Diego; 1971.
21. Fontani G, Corradeschi F, Felici A, Alfatti F, Migliorini S, Lodi L: Cognitive
and physiological effects of Omega-3 polyunsaturated fatty acid
supplementation in healthy subjects. Eur J Clin Invest 2005, 35:691-699.
22. Fava GA: Assessing depressive symptoms across cultures: Italian
validation of the CES-D self-rating scale. J Clin Psychol 1983, 39:249-251.
23. Bos MJ, Lindén T, Koudstaal PJ, Hofman A, Skoog I, Breteler MM,
Tiemeier H: Depressive symptoms and risk of stroke: the Rotterdam
Study. J Neurol Neurosur Psychiatry 2008, 79:997-1001.
24. Apolone G, Mosconi P: The Italian SF-36 Health Survey: translation,
validation and norming. J Clin Epidemiol 1998, 51:1025-1036.
25. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple
methods for the estimation of free testosterone in serum. J Clin
Endocrinol Metab 1999, 84:3666-3672.
26. Fabbri A, Giannetta E, Lenzi A, Isidori AM: Testosterone treatment to
mimic hormone physiology in androgen replacement therapy. A view
on testosterone gel and other preparations available. Expert Opin Biol
Ther 2007, 7:1093-1106.
27. Ballantyne JC: Chronic pain following treatment for cancer: the role of
opioids. Oncologist 2003, 8:567-575.
28. Delitala G, Giusti M, Mazzocchi G, Granziera L, Tarditi W, Giordano G:
Participation of endogenous opiates in regulation of the hypothalamic-
pituitary-testicular axis in normal men. J Clin Endocrinol Metab 1983,
57:1277-1281.
29. Vuong C, Van Uum HM, O’Dell LE, Lutfy K, Friedman TC: The effects of
opioids and opioid analogs on animal and human endocrine systems.
Endocr Rev 2010, 31:98-132.
30. Fabbri A, Jannini EA, Gnessi L, Ulisse S, Moretti C, Isidori A: Neuroendocrine
control of male reproductive function. The opioid system as a model of
control at multiple sites. J Steroid Biochem 1989, 32:145-150.
31. Ceccarelli I, Rossi A, Maddalena M, Weber E, Aloisi AM: Effects of morphine
on testosterone levels in rat C6 glioma cells: modulation by anastrozole.
J Cell Physiol 2009, 221:1-4.
32. Aloisi AM, Ceccarelli I, Fiorenzani P, Maddalena M, Rossi A, Tomei V,
Sorda G, Danielli B, Rovini M, Cappelli A, Anzini M, Giordano A: Aromatase
and 5-alpha reductase gene expression: modulation by pain and
morphine treatment in male rats. Mol Pain 2010, 6:69.
33. Aloisi AM, Buonocore M, Merlo L, Galandra C, Sotgiu A, Bacchella L,
Ungaretti M, Demartini L, Bonezzi C: Chronic pain therapy and
hypothalamic-pituitary-adrenal axis impairment. PNEC 2011.
doi:10.1186/1477-7827-9-26
Cite this article as: Aloisi et al.: Hormone replacement therapy in
morphine-induced hypogonadic male chronic pain patients.
Reproductive Biology and Endocrinology 2011 9:26.
Aloisi et al. Reproductive Biology and Endocrinology 2011, 9:26
http://www.rbej.com/content/9/1/26
Page 10 of 10